Insider Selling: Disc Medicine (NASDAQ:IRON) Insider Sells $123,675.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 1,649 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $123,675.00. Following the completion of the transaction, the insider directly owned 52,173 shares of the company’s stock, valued at $3,912,975. This represents a 3.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Rahul Khara also recently made the following trade(s):

• On Friday, June 26th, Rahul Khara sold 851 shares of Disc Medicine stock. The shares were sold at an average price of $75.00, for a total value of $63,825.00.
• On Thursday, June 18th, Rahul Khara sold 7,500 shares of Disc Medicine stock. The stock was sold at an average price of $70.22, for a total value of $526,650.00.

Disc Medicine Stock Performance

Shares of IRON stock opened at $76.26 on Friday. Disc Medicine, Inc. has a 1-year low of $40.00 and a 1-year high of $99.50. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $2.91 billion, a price-to-earnings ratio of -11.52 and a beta of 0.97. The stock’s fifty day simple moving average is $69.23 and its 200-day simple moving average is $70.39.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.03). On average, sell-side analysts predict that Disc Medicine, Inc. will post -6.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Wedbush restated an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a report on Wednesday, June 10th. Morgan Stanley upped their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, June 15th. Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Disc Medicine has a consensus rating of “Moderate Buy” and a consensus price target of $104.44.

Hedge Funds Weigh In On Disc Medicine

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IRON. Assenagon Asset Management S.A. increased its stake in shares of Disc Medicine by 3,329.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock worth $28,416,000 after purchasing an additional 347,403 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Disc Medicine in the 3rd quarter valued at $6,752,000. SG Americas Securities LLC boosted its holdings in Disc Medicine by 161.9% in the fourth quarter. SG Americas Securities LLC now owns 21,122 shares of the company’s stock worth $1,677,000 after purchasing an additional 13,058 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Disc Medicine by 3.7% in the third quarter. Vanguard Group Inc. now owns 1,448,059 shares of the company’s stock worth $95,688,000 after purchasing an additional 51,323 shares in the last quarter. Finally, First Light Asset Management LLC acquired a new position in Disc Medicine during the third quarter worth $15,277,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.